Sanguine Overview
- Year Founded
-
2010

- Status
-
Private
- Employees
-
139

- Latest Deal Type
-
Later Stage VC
- Investors
-
20
Sanguine General Information
Description
Developer of personalized medicines intended to bridge the gap between patients and researchers. The company provides tools and concierge services that empower patients to participate in research from home and deliver transparency throughout the research process, enabling patients to participate in medical research and have a direct impact on the development of new treatments.
Contact Information
Website
www.sanguinebio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Healthcare Technology Systems
Other Industries
Biotechnology
Other Healthcare Services
Drug Discovery
Primary Office
- 400 West Cummings Park
- Suite 3050
- Woburn, MA 01801
- United States
+1 (855) 000-0000
Sanguine Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
8. Later Stage VC | 09-Jan-2023 | 00.000 | Completed | Generating Revenue | ||
7. Secondary Transaction - Private | 00.000 | Completed | Generating Revenue | |||
6. Debt - PPP | 08-Apr-2020 | 00.000 | Completed | Generating Revenue | ||
5. Grant | 01-Feb-2019 | 00000 | 00.000 | Completed | Generating Revenue | |
4. Accelerator/Incubator | 18-Mar-2018 | 00.000 | Completed | Generating Revenue | ||
3. Later Stage VC | 01-Jul-2016 | 00000 | 00.000 | Completed | Generating Revenue | |
2. Later Stage VC (Series A) | 29-May-2015 | $5.53M | $7.03M | 000.00 | Completed | Startup |
1. Seed Round | 21-Feb-2013 | $1.5M | $1.5M | 00.00 | Completed | Startup |
Sanguine Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series A | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Sanguine Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Developer of personalized medicines intended to bridge the gap between patients and researchers. The company provides to
Other Healthcare Technology Systems
Woburn, MA
139
As of 2023
00.000
0000000000 0
00.000
Sanguine Competitors (10)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Evox Therapeutics | Venture Capital-Backed | Oxford, United Kingdom | 000 | 00000 | 00000000000 | 00000 |
000000 | Venture Capital-Backed | Chicago, IL | 0000 | 00.000 | 000000000 00 | 00.000 |
00000 000 | Formerly VC-backed | Cherry Hill, NJ | 0 | 000.00 | 000000000 | 000.00 |
000000 00000000000 | Venture Capital-Backed | Ghent, Belgium | 00 | 00000 | 00000000000 | 00000 |
0000000000 0000000 | Formerly VC-backed | Cambridge, MA | 0000 | 00000 | 00000000000 |
Sanguine Executive Team (11)
Sanguine Board Members (7)
Name | Representing | Role | Since |
---|---|---|---|
Aaron Fisher | BroadOak Capital Partners | Board Member | 000 0000 |
Benjamin Weiss | Heliant Ventures | Board Observer | 000 0000 |
Brian Neman | Sanguine | Co-Founder, Chief Executive Officer & Board Member | 000 0000 |
Marvin Yee | Self | Board Member | 000 0000 |
Timothy Triche Ph.D | Self | Board Member | 000 0000 |
Sanguine Signals
Sanguine Investors (20)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Albany Capital (Australia) | Venture Capital | Minority | 000 0000 | 000000 0 | |
BroadOak Capital Partners | Growth/Expansion | Minority | 000 0000 | 000000 0 | |
Vitamin Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
National Science Foundation | Government | 000 0000 | 000000 0 | ||
StartUp Health | Venture Capital | Minority | 000 0000 | 000000 0 |